Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight

Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight

Scientific Reports

10.1038/s41598-022-18309-2

https://doi.org/10.1038/s41598-022-18309-2

Oliver C. Watkins, Preben Selvam, Reshma Appukuttan Pillai, Victoria K. B. Cracknell-Hazra, Hannah E. J. Yong, Neha Sharma, Amaury Cazenave-Gassiot, Anne K. Bendt, Keith M. Godfrey, Rohan M. Lewis, Markus R. Wenk, Shiao-Yng Chan

placenta, lipid metabolism, Docosahexaenoic acid, maternal glycaemia, Body mass index

01 September 2022

Watkins, O. C., Selvam, P., Pillai, R. A., Cracknell-Hazra, V. K. B., Yong, H. E. J., Sharma, N., Cazenave-Gassiot, A., Bendt, A. K., Godfrey, K. M., Lewis, R. M., Wenk, M. R., & Chan, S.-Y. (2022). Myo-inositol moderates maternal BMI and glycemia related variations in in-vitro placental 13C-DHA-metabolism, altering their relationships with birthweight. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-18309-2

Transplacental docosahexaenoic-acid (DHA) supply for fetal development is regulated by placental DHA-lipid metabolism. Both maternal diabetes and obesity are linked to possible decreased fetal circulating DHA and increased placental DHA-lipids. Since myo-inositol is a promising intervention for gestational diabetes (GDM), we aimed to determine whether myo-inositol could rectify perturbations in placental DHA metabolism associated with maternal increasing glycemia and obesity and examine links with birthweight. Term placental villous explants from 17 women representing a range of BMIs and mid-gestational glycemia, were incubated with 13C-labeled-DHA for 48 h, in 0.3 µmol/L (control) or 60 µmol/L myo-inositol. Individual newly synthesized 13C-DHA-labeled lipid species were quantified by liquid-chromatography-mass-spectrometry. Compared with controls, incubation with myo-inositol decreased most 13C-DHA-lipids in placental explants from women with higher BMI or higher glycemia, but increased 13C-DHA-lipids with normal BMI or lower glycemia. Myo-inositol also increased 13C-DHA-labeled lipids in cases of lower birthweight centile, but induced decreases at higher centiles. Myo-inositol therefore lowered DHA-lipids in placenta with high basal placental DHA-lipid production (higher BMI and glycemia) but increased DHA-lipids where basal processing capacity is low. Myo-inositol thus moderates placental DHA metabolism towards a physiological mean which may in turn moderate birthweight.

Attribution 4.0 International (CC BY 4.0)

This research is supported by Clinician Scientist Awards awarded to SYC from the Singapore National Medical Research Council (NMRC/CSA-INV/0010/2016, MOH-CSAINV19nov-0002), by the National University of Singapore, National University Health System Singapore and the Singapore Institute for Clinical Sciences A*STAR. The Singapore Lipidomics Incubator receives funding from the Life Sciences Institute, the National University of Singapore Yong Loo Lin School of Medicine, the National Research Foundation Investigatorship (grant number NRFI2015- 05) and A*STAR (IAF-ICP I1901E0040).

This research / project is supported by the Agency for Science, Technology and Research - Industry Alignment Fund – Industry Collaboration Projects
Grant Reference no. : I1901E0040

https://oar.a-star.edu.sg/communities-collections/articles/21988

2045-2322

Institute for Human Development and Potential

https://doi.org/10.1038/s41598-022-18309-2